Iordanis/Jordan Kesisoglou

Ph.D. in Chemical and Biomolecular Engineering | popPK/PD & QSP Modeling | Data Analysis | Simulation | Experimental validation | Process Control

Houston, Texas, United States

About

Highly motivated and skilled Chemical and Biomolecular Engineer (PhD.). My research specialization is in modeling, simulating, and optimizing pharmacokinetics and pharmacodynamics systems. My goal is to use my broad modeling and experimental skills in new challenges within the field of drug development. Expertise: Modeling, Data Analysis, Simulation, Programming, Statistics, Process engineering, Experimental validation, PK/PD analysis, Process control. Software: NONMEM, R, MATLAB

Experience

  • Senior PK/PD Scientist at Labcorp
    Aug 2024 - Present · 1 yr 11 mos

  • Editorial Board Member at Frontiers
    Aug 2023 - Present · 2 yrs 11 mos

    Review Editor on the Editorial Board of Antimicrobials, Resistance and Chemotherapy

  • Senior Scientist at Merck
    May 2022 - Jun 2024 · 2 yrs 2 mos

    Quantitate Pharmacology & Pharmacometrics

  • University of Houston (Houston, Texas, United States)
    • Researcher
      Oct 2021 - May 2022 · 8 mos

      “PKPD Modeling, Optimization and Treatment Prognostics from Modified Plate Reader Measurements for Resistant Fungi “Advisor: Dr. Michael Nikolaou; Associate Advisor Dr. Kontoyiannis o Experiments: Susceptibility breakpoints & Synergy assay Affiliated Organization: MD Anderson Cancer Center

    • Teaching Assistant
      Aug 2018 - May 2022 · 3 yrs 10 mos

      Graded assignments and tutored undergraduate and graduate students: ▪ CHEE 6331 - Mathematical Methods in Chemical Engineering ▪ CHEE 4367 - Chemical Reaction Engineering ▪ CHEE 3321 - Analytical Methods for Chemical Engineers ▪ CHEE 3334 - Statistical / Numerical Techniques for Chemical Engineers

    • Research Assistant
      Aug 2018 - May 2022 · 3 yrs 10 mos

      ▪ Developed a Method to Distinguish Between Dead and Alive Bacteria from Optical Density Measurements when Bacteria are Treated or Not with Antimicrobial Agents ▪ Reverse Engineered the Above Approach to Allow the Medical device to Self-Calibrate the Data Produced ▪ Developed the New State of the Art for the Simultaneous Simulation and Experimentation of Multiple Drugs with Different Half-Lives. ( High Impact in Combinational Therapy) ▪Optimized the Design and Operation of a Hydrogen Network for Transportation Fuel

  • Cell Therapy Translation Engine Clinical Pharmacology & Modeling Chemical and Biomolecular Engineer at Takeda Oncology
    Jun 2021 - Aug 2021 · 3 mos

    Development of a QSP Model for DLBCL NHL disease and application towards Cell Therapies ▪ Develop a QSP model for Diffuse Large B-cell Lymphoma ▪ Integrate the disease QSP model (Aim 1) with a cellular kinetic model of cell therapies to characterize expansion and persistence of CAR-Ts ▪ Explore multiple infusion (if any) datasets in DLBCL patients